Please use this identifier to cite or link to this item:
Type of publication: conference paper
Type of publication (PDB): Konferencijų tezės nerecenzuojamuose leidiniuose / Conference theses in non-peer-reviewed publications (T2)
Field of Science: Biologija / Biology (N010)
Author(s): Pivoriūnaitė, Miglė;Stukas, Darius;Žilinskas, Justas;Šilkūnienė, Giedrė;Šilkūnas, Mantas;Dambrauskas, Žilvinas;Gulbinas, Antanas;Tamelis, Algimantas
Title: HAMLET cytotoxicity in colorectal cancer cell models with different mutation status in Vitro
Is part of: Open readings 2020: 63nd international conference for students of physics and natural sciences, March 17-20, 2020, Vilnius, Lithuania: abstracts book. Vilnius : Vilnius University, 2020
Extent: p. 93-93
Date: 2020
ISBN: 9786090703779
Abstract: HAMLET (Human Alpha-lactalbumin Made LEthal to Tumor cells) is a proteolipid complex of partially unfolded α-lactalbumin and several oleate residues. Its efficacy as a selective killer of tumor cells has been documented in vitro and in vivo in several animal models [1]. HAMLET interacts with multiple tumor cell compartments, affecting cell morphology, metabolism, proteasome function, chromatin structure and cell viability [2]. Colorectal cancer is one of the most frequent malignancies worldwide, being second in males and third in females for its frequency and ranking fourth and third for cancer-related deaths among males and females, respectively [3]. KRAS and BRAF are major oncogenic drivers of colorectal cancer (CRC) [4]. The aim of this study was to evaluate antitumoral activity of the HAMLET complex on three different CRC cell lines (LoVo, WiDr, Caco-2) with different mutation status (KRAS/BRAF, wild type). HAMLET complex was prepared using controlled temperature (partial protein unfold) combined with mixing/shaking with olein acid additive (acid incorporation in protein structure) [5]. Cytotoxicity of complex (metabolic activity and viability of the cells) was evaluated using 6 h exposition and different concentration in compliance with MTT and clonogenic assay protocols. The results suggest that HAMLET affects cell metabolism, this effect is severe and at the same time irreparable for cells, leading to cell death. The complex exhibits cytotoxicity in dose-response manner against all cell lines. However, BRAF mutant cells seems to be more resistant to HAMLET in comparison to KRAS mutants and wild type cells. HAMLET has anticancer potency for CRC in in vitro model
Affiliation(s): Gamtos mokslų fakultetas
Lietuvos sveikatos mokslų universitetas. Medicinos akademija
Vytauto Didžiojo universitetas
Appears in Collections:Universiteto mokslo publikacijos / University Research Publications

Files in This Item:
marc.xml8.99 kBXMLView/Open

MARC21 XML metadata

Show full item record
Export via OAI-PMH Interface in XML Formats
Export to Other Non-XML Formats

CORE Recommender

Page view(s)

checked on Mar 30, 2021


checked on Mar 31, 2021

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.